Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$52.03 USD

52.03
731,989

+0.17 (0.33%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

CVS Health (CVS) to Expand Health Care Access With New Pact

CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

Veeva Systems' (VEEV) slew of product launches raises optimism about the stock.

Abbott's (ABT) New FDA Approval to Improve Patient Outcome

Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.

Here's Why You Should Retain Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

Walgreens Boots (WBA) continues to progress in transforming the pharmacy business and the method of delivering healthcare through physical stores and digital channels.

Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials

Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.

AMN vs. DOCS: Which Stock Is the Better Value Option?

AMN vs. DOCS: Which Stock Is the Better Value Option?

Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%

Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.

Charles River (CRL) to Develop RNA-based Therapy With New Pact

Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.

ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues

ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.

Down -8.76% in 4 Weeks, Here's Why You Should You Buy the Dip in AMN Healthcare (AMN)

AMN Healthcare (AMN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays

Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome

Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.

Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe

Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.

AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know

In the latest trading session, AMN Healthcare Services (AMN) closed at $105.03, marking a +1.13% move from the previous day.

Why You Should Keep Acadia Healthcare (ACHC) in Your Portfolio

The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement

IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

BD's (BDX) New Robotic Track System to Boost Lab Workflow

BD's (BDX) new robotic track system for the BD Kiestra microbiology laboratory solution is expected to streamline lab workflows.

The Zacks Analyst Blog Highlights AMN Healthcare Services, Clarivate, Core & Main, CRH and Deere & Co.

AMN Healthcare Services, Clarivate, Core & Main, CRH and Deere & Co. are part of the Zacks top analyst blog.

Zacks.com featured highlights include StoneX Group, Harte Hanks, Veritiv and AMN Healthcare Services

StoneX Group, Harte Hanks, Veritiv and AMN Healthcare Services are part of the Zacks Screen of the Week article.